Compare AbCellera Biologics Inc (ABCL) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Orion Office REIT Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Orion Office REIT Inc trades at $2.78 (market cap $157.99M). The key difference: AbCellera Biologics Inc is far larger — about 14.9× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.88% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ONL | |
|---|---|---|
Market Cap | $2.35B | $157.99M |
Sector | Health | Real Estate |
52-Week High | $8.12 | $3.04 |
52-Week Low | $2.78 | $1.93 |
Enterprise Value | $1.99B | $641.64M |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ONL trades at $2.78, down 1.77% on the day, with a neutral technical signal and bearish moving averages. The company shows a gross margin of 56.71% but deep net losses, with revenue declining from $208M in 2022 to $148M in 2025. Recent news highlights progress on leasing and strategic reviews, while cash flow remains positive but shrinking.
Outlook is cautious due to persistent losses and high debt, though strategic asset sales and refinancing reduce near-term risks. The 50% analyst buy rating offers some optimism, but investors face significant fundamental challenges amid the troubled office REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
